β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: Systematic review and meta-analysis of randomized controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 41-47

  Shiber, Shachaf ^a   Yahav, Dafna ^a,b   Avni, Tomer ^a   Leibovici, Leonard ^a,b   Paul, Mical ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Rambam Health Care Center   (Israel)

Author keywords

Antibiotic treatment; BL BLIs; ESBLs

Indexed keywords

BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; BETA LACTAM;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SUPERINFECTION; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FOLLOW UP; HOSPITAL INFECTION; HUMAN; META ANALYSIS; MORTALITY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; SURVIVAL;

BACTERIAL INFECTIONS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; CLOSTRIDIUM DIFFICILE; DIARRHEA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84928345136     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku351     Document Type: Article

References (44)

1. Heuer O. EARS-Net results 2011. In: ECDC, ed. First Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, Warsaw, Poland, 2011.
2. Isendahl J, Turlej-Rogacka A, Manjuba C et al. Fecal carriage of ESBL-producing E. coli and K. pneumoniae in children in Guinea-Bissau: a hospital-based cross-sectional study. PLoS One 2012; 7: e51981.
3. Ben Sallem R, Ben Slama K, Estepa V et al. Prevalence and characterisation of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates in healthy volunteers in Tunisia. Eur J Clin Microbiol Infect Dis 2012; 31: 1511-6.
4. Wickramasinghe NH, Xu L, Eustace A et al. High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK. J Antimicrob Chemother 2012; 67: 1108-13.
5. Stromdahl H, Tham J, Melander E et al. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis 2011; 30: 1159-62.
6. Bouchillon S, Hackel M, Hawser S et al. Tigecycline in vitro activity against extended spectrum β-lactamase producers in Latin America-TEST 2008-2010. In: Abstracts of the Forty-ninth IDSA Annual Meeting, Boston, MA, USA, 2011. Abstract 244. IDSA, Boston, MA, USA.
7. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (Updated September 2009). The Cochrane Collaboration, 2009. www.cochrane-handbook.org.
8. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
9. Allo MD, Bennion RS, Kathir K et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 1999; 65: 99-104.
10. Bodey G, Abi-Said D, Rolston K et al. Imipenem or cefoperazonesulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996; 15: 625-34.
11. Dela Pena AS, Asperger W, Kockerling F et al. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intraabdominal infections requiring surgical intervention. J Gastrointest Surg 2006; 10: 567-74.
12. Demir HA, Kutluk T, Ceyhan M et al. Comparison of sulbactamcefoperazone with carbapenems as empirical monotherapy for febrile neutropenic children with lymphoma and solid tumors. Pediatr Hematol Oncol 2011; 28: 299-310.
13. Erasmo AA, Crisostomo AC, Yan LN et al. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg 2004; 27: 227-35.
14. Graham DR, Lucasti C, Malafaia O et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-8.
15. Grayson ML, Gibbons GW, Habershaw GM et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-93.
16. Jaccard C, Troillet N, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72.
17. Joshi M, Metzler M, McCarthy M et al. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006; 100: 1554-65.
18. Lipsky BA, Armstrong DG, Citron DM et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-703.
19. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002; 19: 95-103.
20. Namias N, Solomkin JS, Jensen EH et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt) 2007; 8: 15-28.
21. Oztoprak N, Piskin N, Aydemir H et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010; 40: 761-7.
22. Rea-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-26.
23. Reich G, Cornely OA, Sandherr M et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 2005; 130: 265-70.
24. Roy S, Higareda I, Angel-Muller E et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003; 11: 27-37.
25. Saltoglu N, Dalkiran A, Tetiker T et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 2010; 16: 1252-7.
26. Schmitt DV, Leitner E, Welte T et al. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006; 34: 127-34.
27. Solomkin JS, Yellin AE, Rotstein OD et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235-45.
28. Winston DJ, Bartoni K, Bruckner DA et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998; 26: 576-83.
29. Yanagihara K, Fukuda Y, Seki M et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006; 4b5: 995-9.
30. Yellin AE, Johnson J, Higareda I et al. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg 2007; 194: 367-74.
31. Ito I, Kadowaki S, Tanabe N et al. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. Pulm Pharmacol Ther 2010; 23: 403-10.
32. Marra F, Reynolds R, Stiver G et al. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998; 31: 355-68.
33. Vural S, Erdem E, Gulec SG et al. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2010; 52: 262-7.
34. Eklund AE, Nord CE. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intraabdominal infections. Swedish Study Group. J Antimicrob Chemother 1993; 31 Suppl A: 79-85.
35. Figuera A, Rivero N, Pajuelo F et al. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)]. Med Clin (Barc) 2001; 116: 610-1.
36. Niinikoski J, Havia T, Alhava E et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176: 255-61.
37. Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-31.
38. Catena F, Vallicelli C, Ansaloni L et al. T.E.A. Study: three-day ertapenem versus three-day ampicillin-sulbactam. BMC Gastroenterol 2013; 13: 76.
39. Yamamoto Y, Izumikawa K, Morinaga Y et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. J Infect Chemother 2013; 19: 291-8.
40. Paterson D. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
41. Paterson D, Ko W, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extendedspectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
42. Rodríguez-Baño J, Navarro M, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extendedspectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-74.
43. Vardakas K, Tansarli G, Rafailidis P et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-803.
44. Australian New Zealand Clinical Trials Registry. Trial fromANZCTR. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363706.